BHCM
ABEO icon

Brevan Howard Capital Management’s Abeona Therapeutics ABEO Stock Holding History

Brevan Howard Capital Management’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-29,263
Closed -$131K – 2031
2026
Q1 		$131K Buy
29,263
+7,556
+35% +$37.8K ﹤0.01% 1981
2025
Q4 		$114K Buy
+21,707
New +$109K ﹤0.01% 1666

Other funds holding ABEO

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OIA
OneDigital Investment Advisors Overland Park, Kansas $11.8B AUM 21.23% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Brevan Howard Capital Management's ABEO Position: Q2 2026 in Review

Brevan Howard Capital Management sold out of Abeona Therapeutics (ABEO) in Q2 2026, closing a stake of 29,263 shares — an estimated $131K sold.

Brevan Howard Capital Management first reported a position in ABEO in Q4 2025 and held it in 2 quarters. The position peaked at $131K in Q1 2026. 126 funds tracked by Wall St. Rank hold ABEO as of Q2 2026.

  • Brevan Howard Capital Management reported no remaining Abeona Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Brevan Howard Capital Management sold 29,263 Abeona Therapeutics shares in Q2 2026, an estimated $131K.
  • Brevan Howard Capital Management first reported a position in Abeona Therapeutics in Q4 2025 and held it in 2 quarters.
  • Brevan Howard Capital Management's Abeona Therapeutics position peaked at $131K in Q1 2026.
  • 126 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.